<DOC>
	<DOCNO>NCT00017680</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine response , disease-free survival , overall survival patient primary light chain amyloidosis treat high-dose melphalan autologous stem cell transplantation . II . Determine toxicity regimen patient .</brief_summary>
	<brief_title>Study High-Dose Melphalan Autologous Stem Cell Transplantation Patients With Primary Light Chain Amyloidosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients may receive induction chemotherapy study entry . Patients receive filgrastim ( G-CSF ) another growth factor 4-6 day peripheral blood stem cell ( PBSC ) mobilization . PBSC ( bone marrow ) harvest 2-3 day . Patients receive high-dose melphalan IV 30 minute twice daily day -2 -1 . PBSC and/or bone marrow reinfused day 0 . Patients receive G-CSF beginning day 0 continue blood count recover . This course may repeat 4-12 week later . Patients follow every 3 month 1 year annually 5 year .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm primary amyloidosis Ineligible high priority national international study Prior/Concurrent Therapy Biologic therapy : Concurrent participation gene therapy trial allow Chemotherapy : Prior chemotherapy allow No concurrent chemotherapy Endocrine therapy : No concurrent steroids unless give amphotericin B , adrenal failure , septic shock No concurrent hormone except nondiseaserelated condition ( e.g. , insulin diabetes ) Other : No concurrent barbiturates acetaminophen Concurrent participation supportive care trial allow Patient Characteristics Performance status : ECOG 03 Hepatic : Bilirubin le 2 time normal Renal : Creatinine le 2.5 mg/dL OR On stable hemodialysis Pulmonary : DLCO least 60 % predict OR Clearance pulmonologist Other : HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematopoietic/lymphoid cancer</keyword>
	<keyword>oncologic disorder</keyword>
	<keyword>plasma cell neoplasm</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>rare disease</keyword>
</DOC>